Analysed ADAGENE INC-ADR (ADAG:NASDAQ) News Sources
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
20-04-2026
yahoo.com
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
17-04-2026
yahoo.com
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
14-04-2026
yahoo.com
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed?
05-04-2026
yahoo.com
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
02-04-2026
yahoo.com
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
02-04-2026
yahoo.com
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
17-03-2026
yahoo.com
What is the current price of ADAGENE INC-ADR (ADAG:NASDAQ)?
The current price of ADAGENE INC-ADR (ADAG:NASDAQ) is $3.8.
ADAGENE INC-ADR (ADAG:NASDAQ) absolute price change since previous trading day?
The absolute price change of ADAGENE INC-ADR (ADAG:NASDAQ) since the previous trading day is $0.
ADAGENE INC-ADR (ADAG:NASDAQ) percentage price change since previous trading day?
The percentage price change of ADAGENE INC-ADR (ADAG:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for ADAGENE INC-ADR (ADAG:NASDAQ)?
The most recent average sentiment score for ADAGENE INC-ADR (ADAG:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for ADAGENE INC-ADR (ADAG:NASDAQ)?
The most recent sentiment for ADAGENE INC-ADR (ADAG:NASDAQ) is .
SEC-8K** Filing Available For ADAGENE INC-ADR (ADAG:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.